Comparison of Plasma Concentrations of Posaconazole with the Oral Suspension and Tablet in Korean Patients with Hematologic Malignancies.

Author: Hyeon Jeong SUH ¹ ; Inho KIM ; Joo Youn CHO ; Sang In PARK ; Seo Hyun YOON ; Jeong Ok LEE ; Youngil KOH ; Kyoung Ho SONG ; Pyoeng Gyun CHOE ; Kyung Sang YU ; Eu Suk KIM ; Hong Bin KIM ; Soo Mee BANG ; Nam Joong KIM ; Sang Hoon SONG ; Wan Beom PARK ; Myoung Don OH
Author Information

1. Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea. wbpark1@snu.ac.kr
Publication Type:Brief Communication
Keywords: Posaconazole; Antifungal agents; Tablet; Dosage forms
MeSH: Antifungal Agents; Biological Availability; Dosage Forms; Drug Therapy; Hematologic Neoplasms*; Humans; Plasma*; Remission Induction; Tablets
From:Infection and Chemotherapy 2017;49(2):135-139
CountryRepublic of Korea
Language:English
Abstract: The posaconazole tablet formulation was developed to have improved bioavailability compared to the oral suspension. Here, we compared posaconazole plasma concentration (PPC) with the posaconazole oral suspension versus the tablet in Korean patients undergoing remission induction chemotherapy for hematologic malignancies. PPC was measured at 3, 8, and 15 days of treatment with the oral suspension (174 patients) or the tablet (40 patients). At all time-points, mean PPC was significantly higher with the tablet compared to the oral suspension. Our findings suggest that posaconazole tablets generate an optimal PPC earlier and in more patients than the oral suspension among Korean patients.